Deltaretrovirus infections are primarily associated with the Human T-Cell Lymphotropic Virus (HTLV), a group of retroviruses that predominantly infect T lymphocytes. HTLV is divided into subtypes, with HTLV-1 and HTLV-2 being the most clinically significant. HTLV-1 is linked to various diseases, including Adult T-Cell Leukemia/Lymphoma (ATLL) and a progressive neurological disorder known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Infection occurs through contact with contaminated blood, sexual transmission, and from mother to child through breastfeeding. While the majority of individuals infected with HTLV-1 remain asymptomatic carriers, a subset develops severe complications. Diagnosis involves serological testing and molecular assays. There is no specific antiviral treatment for HTLV-1, and management focuses on treating associated conditions. Prevention strategies include promoting safe sexual practices, avoiding sharing of needles, and discouraging breastfeeding in infected mothers to reduce transmission risk.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain
Title : Mathematical modeling of COVID-19 dynamics in a West African context
Christabel Emaeyak James, University of Glasgow, United Kingdom
Title : Severe influenza and other related respiratory infection cases during Omicron era in Japan
Masafumi Seki, Saitama Medical University International Medical Center, Japan